Erythropoietin-Stimulating Agents

Epoetin alfa reduces anemia but raises clot risk in breast cancer

By

Adding the ESA epoetin alfa to the chemotherapy regimen for high-risk breast cancer improved hemoglobin levels for patients, but it also resulted in increased thrombosis.

Using ESAs in patients with cancer-related anemia

Using ESAs in patients with cancer-related anemia

Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs